Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
490.47
+12.95 (2.71%)
Apr 22, 2025, 4:00 PM EDT - Market closed
Vertex Pharmaceuticals Employees
Vertex Pharmaceuticals had 6,100 employees as of December 31, 2024. The number of employees increased by 700 or 12.96% compared to the previous year.
Employees
6,100
Change (1Y)
700
Growth (1Y)
12.96%
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
126.09B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 6,100 | 700 | 12.96% |
Dec 31, 2023 | 5,400 | 600 | 12.50% |
Dec 31, 2022 | 4,800 | 900 | 23.08% |
Dec 31, 2021 | 3,900 | 500 | 14.71% |
Dec 31, 2020 | 3,400 | 400 | 13.33% |
Dec 31, 2019 | 3,000 | 500 | 20.00% |
Dec 31, 2018 | 2,500 | 200 | 8.70% |
Dec 31, 2017 | 2,300 | 150 | 6.98% |
Dec 31, 2016 | 2,150 | 200 | 10.26% |
Dec 31, 2015 | 1,950 | 120 | 6.56% |
Dec 31, 2014 | 1,830 | 30 | 1.67% |
Dec 31, 2013 | 1,800 | -400 | -18.18% |
Dec 31, 2012 | 2,200 | 200 | 10.00% |
Dec 31, 2011 | 2,000 | 309 | 18.27% |
Dec 31, 2010 | 1,691 | 259 | 18.09% |
Dec 31, 2009 | 1,432 | 99 | 7.43% |
Dec 31, 2008 | 1,333 | 183 | 15.91% |
Dec 31, 2007 | 1,150 | 188 | 19.54% |
Dec 31, 2006 | 962 | 149 | 18.33% |
Dec 31, 2005 | 813 | 77 | 10.46% |
Dec 31, 2004 | 736 | 12 | 1.66% |
Dec 31, 2003 | 724 | -256 | -26.12% |
Dec 31, 2002 | 980 | -20 | -2.00% |
Dec 31, 2001 | 1,000 | 545 | 119.78% |
Dec 31, 2000 | 455 | 102 | 28.90% |
Dec 31, 1999 | 353 | 13 | 3.82% |
Dec 31, 1998 | 340 | 120 | 54.55% |
Dec 31, 1997 | 220 | 42 | 23.60% |
Dec 31, 1996 | 178 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
VRTX News
- 18 hours ago - Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom - Barrons
- 1 day ago - Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely - Benzinga
- 12 days ago - Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis - Business Wire
- 12 days ago - GreensKeeper Q1 2025 Portfolio Update - Seeking Alpha
- 15 days ago - Vertex to Announce First Quarter 2025 Financial Results on May 5th - Business Wire
- 15 days ago - Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers' - Benzinga
- 15 days ago - European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis - Business Wire
- 21 days ago - Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks - CNBC